Riskpilot← Back to searchSign inGet full accessMSD (NORGE) AS
ASActiveOrg 921386540Haakon Viis Gate 5, 0161 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 197482 employeeswww.msd.no
Revenue 2024
NOK 812,1M
+8% vs 2023
EBITDA margin
3.9%
+4% vs 2023
Equity ratio
14.2%
Financial strength
Net profit 2024
NOK 27,8M
+12% vs 2023
| Revenue | NOK 812,1M | +8% |
| EBITDA | NOK 31,8M | +4% |
| Net profit | NOK 27,8M | +12% |
| Total assets | NOK 285,4M | +20% |
| Equity | NOK 40,5M | +8% |
| Employees | 82 | — |
Legal name
MSD (NORGE) AS
Org number
921386540
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
27. mai 1974
Share capital
NOK 4 065 288
Employees
82 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Daglig leder alene.
Company purpose
Produksjon, import, handel og levering av alle typer apotekvarer, farmasøytiske varer og produkter, medisinsk utstyr og tekniske produkter og andre produkter og stoffer til helsevesenet, i tillegg til å markedsføre disse produktene. Dessuten, utvikler og tilbyr selskapet tjenester og produkter relatert til forebygging av sykdommer, oppfølgning av at pasienter gjennomfører foreskrevet behandling, selvbehandling, velferd og effektivisering av driften av helsetjenester.
Address
Haakon Viis Gate 5, 0161 Oslo
Website
www.msd.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 294 174 | 279 053 | 275 157 | 268 866 | 260 806 | 945 779 | 867 396 | 962 740 | 894 805 | 737 127 | 753 229 | 812 145 |
| Staff expenses | −113 646 | −141 230 | −148 945 | −120 029 | −132 928 | −118 042 | −131 510 | −104 656 | −115 166 | −100 245 | −136 355 | −137 941 |
| EBITDA | 20 390 | 13 919 | 14 866 | 10 918 | 2 279 | 36 878 | 26 830 | 41 670 | 35 218 | 31 101 | 30 532 | 31 828 |
| Depreciation & amort. | −1 319 | −1 054 | −928 | −956 | −1 023 | −1 157 | −1 597 | −1 612 | −1 505 | −1 633 | −1 730 | −1 706 |
| EBIT | 19 071 | 12 865 | 13 938 | 9 962 | 1 256 | 35 721 | 25 234 | 40 058 | 33 712 | 29 467 | 28 802 | 30 122 |
| Net financials | −2 140 | −2 649 | −1 301 | −17 | 4 024 | 2 931 | 2 414 | 949 | 238 | 1 591 | 3 212 | 5 636 |
| Profit before tax | 16 931 | 10 216 | 12 637 | 9 944 | 5 280 | 38 652 | 27 648 | 41 006 | 33 951 | 31 058 | 32 014 | 35 758 |
| Tax | 6 459 | 18 964 | 3 233 | 2 421 | 1 190 | 8 873 | 6 199 | 9 058 | 7 532 | 6 923 | 7 156 | 7 958 |
| Net profit | 10 472 | −8 748 | 9 404 | 7 524 | 4 090 | 29 779 | 21 449 | 31 948 | 26 419 | 24 135 | 24 858 | 27 801 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 139 497 | 144 722 | 195 116 | 203 373 | 215 715 | 443 287 | 337 098 | 397 148 | 344 854 | 238 515 | 237 446 | 285 361 |
| Equity | 49 116 | 29 713 | 80 307 | 87 404 | 95 153 | 124 694 | 86 394 | 118 157 | 73 901 | 47 656 | 37 514 | 40 515 |
| Long-term debt | 0 | 0 | 4 688 | 3 660 | 4 547 | 3 239 | 2 330 | 850 | 0 | 0 | 46 | 55 |
| Short-term debt | 61 581 | 65 229 | 83 349 | 89 481 | 102 422 | 305 464 | 241 781 | 273 743 | 268 434 | 190 036 | 199 887 | 244 792 |
| Total debt | 61 581 | 65 229 | 88 037 | 93 140 | 106 969 | 308 702 | 244 111 | 274 593 | 268 434 | 190 036 | 199 932 | 244 847 |
EBITDA margin
3.9%
This company
15.8%
Market median
-75% vs market
20132024
Equity ratio
14.2%
This company
38.2%
Market median
-63% vs market
20132024
Return on equity
68.6%
This company
18.4%
Market median
+273% vs market
20132024
Net profit margin
3.4%
This company
8.1%
Market median
-58% vs market
20132024
Asset turnover
2.85×
This company
1.12×
Market median
+154% vs market
20132024
Debt / equity
6.04×
This company
0.62×
Market median
-874% vs market
20132024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EJ Chief Executive Officer | Chief Executive Officer | 2026 | — | — |
AM Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
IL Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
MA Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Obs Human Health Holding B.V. | Company | 100.0% | 100.0% | 2024 |
Msd Human Health Holding B.V. | Company | 100.0% | 100.0% | 2023 |
| Individual | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MSD (NORGE) AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emma Jayne Setter | Chief Executive Officer | 0 companies |
| Andreea-Aurelia Mocofan | Chief Executive Officer | 0 companies |
| Ingunn Lysaker Norbom | Chief Executive Officer | 0 companies |
| Muhammed Abdur Rauf Ali | Chief Executive Officer | 0 companies |
| Harold Arthur Richard Heere | Board of Directors | 0 companies |
| Funda Zeynep Erdem | Chairman | 0 companies |
| Funda Zeynep Ekincioglu | Chairman | 0 companies |
| Emmanuel Guy Marie Thiery | Chairman | 0 companies |
| Minna Kristiina Mikkola | Board of Directors | 0 companies |
| Bernhard Sauer | Board of Directors | 0 companies |
| Harald Arthur Richard Heere | Board of Directors | 0 companies |